Researchers at the University of Exeter have developed a genetic risk score to predict the likelihood of developing type 1 diabetes, which could be used in large-scale health studies. This test identifies individuals at high risk, allowing for early intervention with drugs like teplizumab, which can delay the onset of the disease. The paper, published in The Lancet Diabetes & Endocrinology, highlights the importance of early detection, as the drug is only effective before symptoms appear.

A study in the journal Diabetes Care found that inhaled Technosphere insulin was safe for children and adolescents with type 1 diabetes, and associated with greater satisfaction and less weight gain when compared with rapid-acting insulin. However, it did not meet noninferiority criteria for HbA1c outcomes.

Being overweight as a child and young adult was linked to a greater likelihood of coronary heart disease in adulthood, but normalizing weight before young adulthood may help reduce the risk, researchers reported in JAMA Pediatrics. The study followed 103,232 people born between 1945 and 1968 for an average of 37.8 years. Overweight as a young adult was associated with a higher risk than overweight as a child, and people who normalized their weight before young adulthood had a CHD risk as adults similar to peers who had maintained a normal weight.

A study in the Annals of Internal Medicine indicates GLP-1 receptor agonists such as Ozempic and Zepbound likely have minimal impact on a person's risk for obesity-related cancers. The study, which analyzed 48 trials involving 94,245 participants, found that the drugs had little to no effect on risk for cancers such as breast, thyroid, pancreatic and kidney. The study's limitations include its short follow-up period and the fact that none of the trials was designed to measure cancer outcomes.

Behavioral changes are key for improving sleep, but the approach to setting these goals is equally important, psychologist Dayna Lee-Baggley said at an American College of Lifestyle Medicine meeting. Lee-Baggley recommends choosing goals that patients are 90% confident they can achieve to build momentum, and suggests "do instead" goals such as drinking a noncaffeinated beverage in the afternoon instead of a caffeinated one.

Early lipid screening can be important for detecting familial hypercholesterolemia in children, especially if they are overweight or have a family history of high cholesterol, experts say. FH affects about 1.3 million people in the US, but only 10% know they have it, according to the American Heart Association. Children with FH can begin treatment as young as age 8, with lifestyle modifications beginning earlier.

People with polycystic ovary syndrome are increasingly using weight-loss drugs from Novo Nordisk and Eli Lilly to manage symptoms, with prescriptions rising sevenfold since 2021, according to an analysis by health data firm Truveta. Doctors and patients note a need for focused studies and approved indications for GLP-1s in PCOS.

Hims & Hers Health is introducing weight-loss treatment in the UK, including Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. The subscription model will offer clinical assessments and ongoing support, similar to US programs.